Aminoglycosides belongs to the class of antibiotics, widely used against bacterial infections caused by Staphylococci, Mycobacterium Tuberculosis and Aerobic gram-negative bacilli. Aminoglycosides and other antibiotics are also used in combination to deliver highly effective therapeutic and medicinal care.  

The global Aminoglycosides antibiotic market size by 2020 was valued at $1051.5M and expected to reach $1083.5M by 2027 by registering 0.5% of CAGR during the forecast period 2021-2027. The major factors driving the market growth include outbreak of animal diseases, increasing prevalence of bacterial infection and rise in cases of tuberculosis. During the outbreak of animal diseases for instance COVID-19, Aminoglycosides works as an immunity enhancer and anti-viral against bacteria causing respiratory infection, which results in the market growth. Along with the increasing prevalence of bacterial infection caused by streptococci and mycobacterium or Aerobic gram negative bacilli, these antibiotics class serves as first line treatment and encourage the growth of market by accomplishing the increasing demand for Aminoglycosides antibiotic. Moreover, for the treatment of tuberculosis, the first line Aminoglycosides anti-biotic drug include streptomycin, kenamycin and Amikacin which are anticipated to enhance the global market during the forecast period.

The key strategy followed by market players to expand their share in the market include focusing on R&D of products. To deal with outbreak of tuberculosis and other bacterial induced diseases, by providing highly-effective medication for the treatment of several therapeutic conditions. 

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Product type

o By Route of Administration

o By Application

o By Distribution Channel

• Competitive Landscape- Jemicare, Teva, Novaratis, fanguan-pharma, Aike- pharma, Cipla, Pfizer, Fresenius Kabi, Sun pharma, Hikma,Lannet Company.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Aminoglycosides Antibiotics Market Report Segment

By Product Type

o Neomycin

o Tobramycin

o Gentamicin

o Amikacin

o Etimicin

o Others

By Route of Administration

o Parentral 

o Topical

o Oral

By Application

o Veterinary

o Skin infection

o Respiratory diseases

o UTI and Pelvic diseases

o Others

By Distribution Channel

o Hospital

o Clinic

o Post care facility

o Government and Military

o Others

Global Aminoglycosides Antibiotics Market Report Segment by Region